+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 55 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of an investigational treatment called RN1101, which are allogeneic CAR-T cells targeting CD19 and BCMA. This early-phase, open-label pilot study focuses on patients with relapsed or refractory B-cell or plasma cell-derived malignant tumors, including B-cell lymphoma and multiple myeloma. The study plans to enroll 21 patients to understand how well this treatment works and its safety profile for these challenging cancers. Participants will receive a single intravenous infusion of RN1101 cells designed to target and attack cancerous B cells or plasma cells. The study involves a dose-escalation approach where all patients receive the experimental therapy. Researchers will monitor the treatments ability to reduce or eliminate cancer cells expressing CD19 or BCMA and evaluate how long these CAR-T cells persist in the body. Throughout the study, participants will be closely followed for up to 24 weeks after the infusion. Researchers will assess safety by tracking adverse events and measure effectiveness using outcomes such as minimal residual disease status, response rates, progression-free survival, overall survival, and CAR-T cell presence in blood and bone marrow. Blood tests, imaging, and clinical evaluations will be performed regularly to monitor treatment response and participant health over this period.

Age: 18Years +All GendersEarly Phase 1
1 location
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of chimeric antigen receptor natural killer CAR NK cells in people who have relapsed or refractory B-cell related autoimmune diseases. This early phase 1 pilot study plans to enroll 15 patients to explore how well CAR NK cells work and how safe they are for treating these conditions. The study also aims to observe the expansion, persistence, and ability of CAR NK cells to deplete B cells in affected patients. Participants will receive chemotherapy drugs Fludarabine and Cyclophosphamide on days -5, -4, and -3 before getting an infusion of CAR NK cells. This treatment is given as a single-arm, open-label intervention without a comparison group. The infusion and follow-up evaluations will monitor safety and treatment effects over time. During the study, participants will be closely followed for safety through monitoring dose-limiting toxicities and treatment-emergent adverse events at multiple time points up to 52 weeks after infusion. Researchers will also assess disease control and remission rates at 4, 12, 24, and 52 weeks. Participants must complete all trial procedures, including regular assessments of organ function, heart performance, and overall health. The total study duration extends from treatment through one year of follow-up.

Age: 18Years - 70YearsAll GendersEarly Phase 1
2 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.

Age: 18Years - 75YearsAll GendersPhase 3
45 locations
A

Actively Recruiting

Researchers are conducting a master protocol study called IIBD to evaluate the safety and effectiveness of new treatments for adults with moderately to severely active ulcerative colitis or Crohns disease. This phase 2, randomized, controlled study includes multiple individual sub-studies that share key design features. Participants are assigned to the appropriate sub-study before being randomized to a treatment group, with the overall study lasting at least 62 weeks. The study treatments include mirikizumab given intravenously IV during the first study period. Responders then receive mirikizumab subcutaneously SC in the second period. Another group will receive oral LY4395089 combined with IV mirikizumab initially, then responders stop LY4395089 and continue with mirikizumab SC. These two treatment approaches are being assessed in parallel groups. Participants will undergo screening to confirm diagnosis and disease activity, followed by regular study visits during the treatment periods. Researchers will monitor laboratory test results and evaluate response to treatment using measures such as the modified Mayo score for ulcerative colitis and the Crohns disease activity index. The primary outcome includes tracking the number of participants assigned to each treatment group up to day 42. The study runs through March 2028 with ongoing safety and efficacy assessments.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations

1-10 of 55

1